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Abstract
Indirect traumatic optic neuropathy (ITON) refers to optic nerve injury resulting from impact remote to the optic
nerve. The mechanism of injury is not understood, and there are no confirmed protocols for prevention, mitigation
or treatment. Most data concerning this condition comes from case series of civilian patients suffering blunt injury,
such as from sports- or motor vehicle-related concussion, rather than military-related ballistic or blast damage.
Research in this field will likely require the development of robust databases to identify patients with ITON and
follow related outcomes, in addition to both in-vivo animal and virtual human models to study the mechanisms
of damage and potential therapies.
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Background
Indirect traumatic optic neuropathy (ITON) is a condi-
tion in which a patient suffers head trauma and is found
to have reduced vision and an afferent pupillary defect
despite a normal acute slit lamp examination and nor-
mal acute magnetic resonance imaging (MRI) and com-
puter tomography (CT) of the optic nerve and canal.
ITON differs substantially from direct traumatic optic
neuropathy (DTON); in DTON, the optic nerve axons
or vascular supply are directly damaged due to strain (as
may be observed in an avulsion of the optic nerve),
compression (as may be observed from edema or
retro-orbital hemorrhage) or transection (as may be
observed from a fracture in the optic canal). Patients
suffering either ITON or DTON can experience pro-
found vision loss after trauma. Prognosis is guarded
in either situation; however, some patients with ITON
may experience full recovery with no intervention. Few
randomized controlled studies have explored therapies for
ITON, and as discussed below, therapies employed to
treat DTON appear to be ineffective for ITON. A comput-
erized search of PubMed (performed October 28, 2015,
search terms: indirect + trauma + optic + nerve) revealed
195 publications on this topic from 1905-present; notably,
a similar search without the word “indirect” produced
4,495 entries. Most publications concerning ITON can be
divided into studies of diagnosis, therapeutic approaches
and pathogenesis. Additionally, the vast majority of
publications report on civilian blunt injuries rather
than blast or ballistic injuries that may be experienced
more commonly by military personnel.
Epidemiology
The incidence of ITON has not been directly reported
in any large population. However, very good surveillance
studies of traumatic optic neuropathy of any type have
been reported for pediatric [1] and adult [2] populations
in England. For both adults and children, the overall
incidence of traumatic optic neuropathy is approxi-
mately 1/million. Notably, approximately 80 % of the
patients were male, and the majority of cases suffered
relatively minor head injuries with neither orbital nor
skull fracture, suggesting that ITON may be more com-
mon than DTON. Visual outcomes ranged from no light
perception (NLP) to normal. One study from India
reported that 35 (or 27 %) of 129 consecutive cases
collected between 1994–2006 suffered ITON following
cranio-orbital injury in two-wheeler riders involved in
road accidents [3]. Notably, these patients reportedly did
not wear protective helmets, suggesting that helmets
may offer protection. Case reports suggest that the
location of the impact, specifically the face, is also a risk
factor for ITON [4–7]. A retrospective study of 379
consecutive patients who underwent repair for facial
fractures in the US reported that blindness developed in
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at least one eye in 21 patients (6 %), 5 of whom had
ITON (1.3 %) [8]. There has been a call to create a registry
specifically for ITON [9]; however, no such registry has
been created. The United States Department of Defense
(DoD) Vision Center of Excellence (VCE), in collaboration
with Veteran Health Affairs, developed a robust registry:
the Defense and Veterans Eye Injury and Vision Registry
(DVEIVR). The vision registry is composed of active duty
service members and veterans with eye trauma and vision
dysfunction/damage to the visual system. This initiative of
the VCE consists of clinical and historical data starting on
9/11/2001 and provides a longitudinal analysis of patients
with trauma and other ocular and visual pathway injuries
[10]; the authors are currently exploring this registry to
determine if it may yield a cohort of patients with trau-
matic optic neuropathy from any cause in general and
ITON in particular.
Diagnosis
By definition, ITON is a condition in which injury to the
optic nerve can be clinically confirmed, i.e., patients
demonstrate reduced visual acuity, color vision, and/or
visual field, as well as a relatively afferent pupillary defect.
Notably, this latter finding may not be present in bilateral
cases. Direct ophthalmoscopy of the nerve is also expected
to appear normal, though optic atrophy or pallor are
expected to develop. Automated visual field testing should
be offered; however, the vision of subjects may be too poor
to glean useful results. In most cases, testing with visual
evoked potentials (VEP) is not needed to establish the
diagnosis. However, in questionable cases, VEP may pro-
vide confirmatory data. VEP may also have predictive
value; patients with better responses on VEP may be
more likely to regain some or all of their vision [11, 12].
VEP has also been employed in the emergency setting to
guide decisions to offer rescue treatment [13]. One case
reported a patient with ITON who was evaluated with
scanning laser polarimetry, which indicated that the
retinal nerve fiber layer acutely thickened and then pro-
gressively thinned for 3 months [14]. This trend was
supported by results from a Chinese study employing
ocular coherence tomographic (OCT) evaluation in 54
patients with ITON. Retinal nerve fiber layer thickness
ultimately decreases in these patients; however, in those
eyes with the worst vision (no light perception [NLP]),
there was a slight increase in thickness in the acute (first
2 weeks) post-injury period [15]. Additionally, this study
explored hemodynamic parameters and demonstrated
that the peak systolic velocity of blood flow within the
central retinal artery was significantly increased in ITON
patients regardless of whether their visual acuity was NLP
or better than NLP.
CT and plain radiographic findings in ITON would, by
definition, exclude fractures in the optic canal because
they would be suggestive findings of DTON. However,
patients with ITON may suffer other skull fractures. A
study of 39 patients with both ITON and peri-orbital
fractures indicated that posterior orbital fracture is
associated with poorer visual outcomes than those
with anterior fractures, suggesting that CT may help
in guiding decisions to offer therapy [16]. MRI, par-
ticularly the diffusion tensor imaging (DTI) technique,
has been applied to the study of ITON. In a study of
28 patients, no differences were noted between the
injured eye and the normal contralateral eye in the
first week after injury. Reduced fractional anisotropy
appeared in the injured eye by the second week, a trend
that continued after one month [17]. These results indi-
cate that MRI may be useful to follow the patient but may
not be as helpful in the initial diagnosis.
Treatment
No therapy has been confirmed to effectively treat ITON,
but observation is considered an acceptable option.
Observational studies of ITON have demonstrated
wide variability in visual function, the rate of recovery
and long-term outcomes. Most patients in the pediatric
TON surveillance study improved or at least did not
worsen from baseline visual acuity [1]. Recovery usually
occurs within the first month after injury [18] but can
occur later at 8 or 12 weeks [12].
Two pilot studies exploring the efficacy of intravenous
(IV) erythropoietin have been published [19, 20]. In
both cases, the drug was administered within 2–3
weeks of onset, and in both cases, the treated cohort
demonstrated improved best corrected visual acuity.
Notably, the rationale for this treatment was that erythro-
poietin may provide neuro-protection and support axonal
growth [21–24].
Corticosteroids have also been offered to patients for
ITON. A Cochrane review from 2013 found one double-
masked, placebo-controlled and randomized study in
which high-dose IV corticosteroids were offered within
1 week of the injury causing ITON; there was no signifi-
cant benefit over observation [25]. This finding was
supported by an even more recent review of multiple
electronic databases [26]. Importantly, a large multi-
center study (MRC CRASH) indicated that high-dose
corticosteroids should not be routinely offered to pa-
tients suffering a head injury due to an elevated risk
of death [27].
A 2010 study investigated the potential additive effect
of providing levodopa-carbidopa to improve the visual
outcomes of patients with indirect traumatic optic neur-
opathy (ITON) [28]. The rationale behind this study
was that steroids should be offered because they were
considered a mainstay of treatment and that the neuro-
protective effect of levodopa may enhance outcomes [29].
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This randomized, double-blind, placebo-controlled study
was completed on 32 patients with ITON within 6 days
after trauma. All patients received high-dose intravenous
methylprednisolone, and levodopa was also administered
to 16 patients. Visual acuity significantly improved in the
levodopa group but not the placebo group. Nine patients
in the levodopa group and 1 in the placebo group experi-
enced improvement in visual acuity; no patients worsened
over time. Recognizing that the evidence supporting the
efficacy of corticosteroids is insubstantial, one must won-
der whether the levodopa-carbidopa itself may provide a
benefit. The neuro-protective effects of levodopa have also
been suggested in more recent studies [30].
Optic canal decompression represents the primary sur-
gical therapy attempted in treating ITON. A number of
retrospective studies provided anecdotal data suggesting
that this surgery can be effective even if offered after a few
weeks of observation or medical therapy [18, 31–37].
However, a Cochrane review in 2005 found no strong
evidence of the efficacy of canal decompression but
did find risks of vision loss, cerebrospinal fluid (CSF)
leak and meningitis [38]. Prior to that, the International
Optic Nerve Trauma Study similarly concluded that nei-
ther steroid therapy nor decompression showed clear
benefits [39].
Transcorneal electrical stimulation (TES) has been
reported to maintain more normal morphology and
increase the survival of rat retinal ganglion cells after
nerve crush [40], to promote axon survival and re-
generation [41], and to support improved function of
the optic nerve [42]. The rationale for offering TES is
that earlier studies suggested that it may have stimu-
lated the production of neuro-protective substances.
TES has been offered to 5 humans suffering from trau-
matic optic neuropathy, 4 of whom reportedly experi-
enced visual improvement [43]. Notably, this publication
specified neither the mechanism of injury causing the
traumatic optic neuropathy nor how that diagnosis was
made. A later study reported that TES increases chor-
oidal blood flow [44]; this was postulated to be neuro-
protective. TES may warrant further exploration due to its
safety and the data supporting its positive effect on photo-
receptors and ganglion cells in animal experiments [45].
Notably, one reported case series found that acupunc-
ture, a traditional Chinese medicine, was successfully
applied to treat ITON [46]. Acupuncture has also
been reported to help patients with ischemic optic
neuropathy [47], though it has not been shown to be
successful in treating glaucoma [48]. Until other ther-
apies are proven beneficial, it appears reasonable to
consider further studying the potential of acupuncture
given its very low risk.
Research on novel neuro-protective medical therap-
ies for optic nerve injury, particularly against glaucoma
[49–54], optic neuritis [55, 56] and direct nerve trauma
[57–62], is flourishing. Additionally, efforts are aimed not
only at sparing retinal ganglion cells but also at regenerat-
ing their axons [63–66]. These therapies are in varying
stages of development but are not currently readily avail-
able to practitioners.
Etiology
Studies suggest that the biomechanical response of the
cranial contents to traumatic loads is an important aspect
in understanding the etiology of ITON. A seminal and
frequently referenced study using holographic interferom-
etry on human skulls reported that frontal loading results
in the deformation of the ipsilateral orbital roof near the
optic foramen [67]. One may suggest that this deform-
ation could damage not only the supporting vasculature of
the optic nerve but could also cause shear stresses to the
nerve, particularly where the nerve enters the canal.
A more recent anatomic study of cadaveric orbits
and optic nerves with the intent of identifying possible
etiologies for ITON was reported in 2002 [68]. Forty-one
specimens were analyzed via light, polarization, immune-
histochemical and scanning electron microscopy. Delicate
anastomoses were reported to run between the dura and
pia in the optic canal, and potential mechanisms of optic
nerve injury include the disruption of the blood supply,
pressure from microhematomas and edema, and direct
shearing injury to axons.
Diffuse axonal damage should also be considered as
a mechanism underlying ITON. Diffuse axonal dam-
age due to injurious inertial force to the head has
been associated with poor neurological outcomes. Rapid
deformations of axons in the white matter tracts of the
brain can lead to damage to the axonal cytoskeleton and
the impairment of axoplasmic transport. Subsequent
swelling and calcium entry into damaged axons can lead
to further dysfunction and physical breakage and add-
itional neuropathological changes in the brain tissue [69].
There is a need to improve the current understanding on
the connection between the biomechanics and patho-
physiology associated with axonal trauma. In vivo experi-
ments that stretched an optic nerve in guinea pigs have
provided tissue-based mechanical criteria for axonal injury
using a measure of strain, which was defined as the ratio
of the amount of extension over the unstretched length
[70]. Integrating these experimentally-derived criteria with
high-fidelity head anatomy from MRI and DTI data within
a physics-based framework have enhanced computational
models of traumatic brain injury (TBI) [71]. For example,
Cirovic et al. [72] performed a finite element analysis of
the human globe and orbit to study the passive mecha-
nisms of eye restraint during head impact trauma; this
study explored ocular changes that may be observed in
shaken baby syndrome. Modeling has been applied to
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understand the biomechanics of glaucomatous injury to
the optic nerve [73–78], compressive injury to the chiasm
[79], blunt injury to the optic nerve [80] and blast injury
to the globe and orbit [81–83]. Data from trauma
modeling in a virtual head and orbit suggest that frontally
applied forces, even of low impact, propagate toward the
optic foramen, supporting the notion that ITON is more
likely to result from facial injuries than from injuries to
other locations on the skull. Despite these advances, the
etiology of ITON remains unclear. A holistic model of the
orbit, including both bone and soft tissue elements, may
bring greater understanding to this blinding illness and
permit strategies for prevention and mitigation. Addition-
ally, a better model would enable studies not only of blunt
injury commonly experienced by civilians but also ballistic
and blast injury in warfare.
Conclusions
Little is known with certainty about the etiology of indir-
ect traumatic optic neuropathy. This sight-threatening
condition may be a relatively common comorbidity of
blunt craniofacial head trauma. Unfortunately, there are
neither proven strategies for prevention, mitigation or
cure, nor are there satisfactory laboratory models to ex-
plore this condition. The authors strongly support the
development and analysis of clinical databases to better
understand the natural history of this condition. Further,
the authors support efforts to create models, both virtual
and real, to clarify the biomechanics of ITON.
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